Epcoritamab for treating relapsed or refractory follicular lymphoma

Epcoritamab is currently in development for treatment of relapsed or refractory follicular lymphoma (FL). FL is a type of non-Hodgkin’s lymphoma (NHL) which affects white blood cells. In FL, the affected white blood cells start to multiply in an abnormal way and begin to aggregate in certain parts of the body such as the lymph nodes. Some FL patients may experience no symptoms. Some symptoms that may occur include painless swelling of the lymph nodes, shortness of breath, fatigue, night sweats and weight loss. A recurrence of lymphoma after going into complete remission is known as a relapse. Lymphoma that is unresponsive to therapy is called refractory lymphoma. The condition can become more difficult to treat if it is relapsed or refractory, as treatment options are limited and often not very effective.